MBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon Buys 47,502 Shares of Stock

Posted by Lauren Steadman on Feb 20th, 2025

MBX Biosciences, Inc. (NYSE:MBX – Get Free Report) Director Carl L. Gordon purchased 47,502 shares of MBX Biosciences stock in a transaction on Friday, February 14th. The shares were acquired at an average cost of $9.87 per share, for a total transaction of $468,844.74. Following the completion of the transaction, the director now owns 3,205,930 shares of the company’s stock, valued at $31,642,529.10. This represents a 1.50 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

MBX Biosciences Stock Performance

Shares of MBX stock opened at $11.22 on Thursday. The firm’s 50 day simple moving average is $14.22. MBX Biosciences, Inc. has a fifty-two week low of $8.63 and a fifty-two week high of $27.50.

Hedge Funds Weigh In On MBX Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company acquired a new position in shares of MBX Biosciences during the third quarter worth about $1,200,000. NEA Management Company LLC acquired a new position in MBX Biosciences during the 3rd quarter worth approximately $93,904,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in MBX Biosciences during the 3rd quarter worth approximately $278,000. Maven Securities LTD acquired a new position in shares of MBX Biosciences during the third quarter worth $1,299,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of MBX Biosciences during the third quarter worth $405,000.

MBX Biosciences Company Profile

(Get Free Report)

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.